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Background: Inflammatory bowel disease (IBD) is a systemic disease that can present with
pulmonary manifestations. IBD may be exacerbated during pregnancy.
Case: We describe the first reported case of pulmonary manifestation of ulcerative colitis
(UC), an IBD, with necrobiotic nodules, in a pregnant patient. A 27-year-old woman with
a history of UC, 25 weeks pregnant, presented to our hospital with bilateral pulmonary
nodules. After serologic and radiologic evaluation, she underwent biopsy by video assisted
thoracic surgery and a tissue diagnosis was made.
Conclusion: This case illustrates the need to consider extra intestinal manifestations of IBD,
the need to establish diagnosis by biopsy, and the consideration of appropriate therapeutics
in the pregnant patient.
ª 2008 Elsevier Ltd. All rights reserved.Case
A 27-year-old woman, para 1, 25 weeks pregnant and with
a history of ulcerative colitis (UC), presented with bilateral
pulmonary nodules. She had been diagnosed with UC at age
19, and treated primarily with mesalamine. At 11 weeks
gestation, she was treated with a 5 week course of steroids0 706 3344; fax: þ1 410 706
.umaryland.edu (G. Netzer).
ll rights reserved.for a flare of her UC. After completing the steroids, she
developed pleuritic chest pain and was given azithromycin
for an abnormal chest radiograph at an outside hospital
(Fig. 1). A second course of steroids was given for a second
flare of her gut disease, exacerbated by NSAID use for her
chest pain, and her gut and pulmonary symptoms improved,
and then worsened after cessation of steroids. She then
presented to our hospital.
The patient had no history of premature fetal demise.
She was diagnosed with UC at age 19 and had been
managed primarily on mesalamine. She had several flares of
her gut disease requiring prednisone but has not undergone
Figure 1 Chest radiograph.
Pulmonary manifestation of inflammatory bowel disease 45endoscopy since the time of her diagnosis. She was a life-
long nonsmoker, drank alcohol occasionally, and had no
history of injection drug use.
Computerized tomography with angiography revealed
bilateral nodules, with no evidence of pulmonary embolism
(Fig. 2). The basic metabolic panel, liver associated
enzymes, and serum complement levels were within normal
limits. The white blood cell count was noteworthy for
a leukocytosis, with a count of 22.3, with a left shift but
normal eosinophil count. Her erythrocyte sedimentation
rate was elevated at 80 but all rheumatologic serologies,
including anti-nuclear antibodies (ANA), anticytoplasmic
antibodies (ANCA), and rheumatoid factor (RF) were
negative, as was human immunodeficiency virus (HIV)
testing. Her beta HCG was within normal limits for herFigure 2 CT scan of the chest.stage of pregnancy, and her blood and urine cultures, and
infectious antibody serologies were negative. A trans-
thoracic echocardiogram revealed no vegetations or
valvular abnormalities. Her hypersensitivity panel was
negative. A computerized tomography-guided transthoracic
needle biopsy was performed but was nondiagnostic.
A broad differential diagnosis was entertained. This
included infectious etiologies, including fungal and bacte-
rial pneumonia and septic emboli, as well as neoplastic
causes, such as choriocarcinoma and metastatic colon
cancer. Attention was most directed towards inflammatory
etiologies, including vasculitis, cryptogenic organizing
pneumonia, eosinophilic pneumonia and hypersensitivity
pneumonitis, and pulmonary manifestations of her UC.
Because of the concern for ANCA-negative Wegener’s
Granulomatosis,1 with previous case reports of pulmonary
vasculitis complicating inflammatory bowel disease (IBD),2,3
the patient proceeded to video assisted thorascopic surgery
and wedge biopsies were obtained (Fig. 3). These showed
a neutrophilic predominant aggregation with areas of
necrosis, without granuloma, and with negative bacterial,
acid fast and fungal stains. She was begun on prednisone,
a corticosteroid chosen because only a small amount of its
dose is presented to the fetus,4 at 80 mg daily with rapid
clinical and radiographic resolution.
Discussion
IBD, comprising of Crohn’s Disease (CD) and Ulcerative
Colitis (UC), is often considered as a disease limited to the
gastroenteric tract. However, its pathophysiology results
in systemic inflammation and a wide variety of extra
intestinal manifestations.5 The immune activation associ-
ated with IBD induces the production of nonspecific
inflammatory mediators, including cytokines, chemokines,
prostaglandins, and leukotrienes.7 A variety of extra
intestinal pathophysiology results, including acute syno-
vitis, sacroiliitis, uveitis and erythema nodosum.5 The lung
can also be involved with airway disease, including gran-
uloma and bronchiectasis, interstitial disease, or pleural
disease, with serositis. Necrobiotic pulmonary nodules areFigure 3 Surgical pathology: Hematoxylin and eosin stain,
200 magnification.
46 G. Netzer, G. Tinoan unusual but well described manifestation of IBD.6
Though no randomized clinical trials have been conducted
to guide the choice of treatment of pulmonary manifes-
tations of IBD, a variety of therapies have been used and
presented in the literature, including inhaled and systemic
corticosteroids, cyclophosphamide, infliximab, and myco-
phenolate mofetil.
In pregnancy, if IBD is active at the time of conception,
two thirds will have relapse or worsening of their disease,
while most with quiescent disease will remain without
active disease during pregnancy.8 This is the first case
presented in the literature of the occurrence of pulmonary
manifestation of IBD in a pregnant patient. Physicians
should consider IBD as a systemic disease and consider
extra-pulmonary disease in their patients with UC and CD.
Additionally, this case illustrates the importance of
obtaining tissue for diagnosis and considerations in choosing
a therapeutic agent appropriate for the pregnant patient.
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